Poltreg (PTG) Investor presentation summary

Scientific foundation and leadership

• Built on Nobel Prize-winning discoveries in regulatory T cells (Tregs) and immune tolerance, with key scientific advisors from leading global institutions.

• Over 15 years of clinical experience and more than 100 patients treated with Treg therapeutics.

Pipeline and clinical programs

• Largest and most advanced pipeline of cell therapies for autoimmune diseases, including polyclonal, CAR-Treg, TCR-Treg, and antigen-specific Tregs.

• Multiple ongoing and planned clinical trials for type 1 diabetes (T1D), multiple sclerosis (MS), ALS, and dermatological conditions.

• PTG-007 + Rituximab demonstrated long-term safety and efficacy in T1D, maintaining insulin secretion and remission for over 7 years.

• First-in-class CD6/CTLA4 CAR-Treg therapy approved for FDA evaluation, targeting advanced T1D and neuroinflammatory diseases.

Manufacturing and infrastructure

• Operates a state-of-the-art, EMA-agreed Class A sterile cell product facility with scalable GMP manufacturing and expansion capacity.